S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
NASDAQ:GDRX

GoodRx (GDRX) Stock Price, News & Analysis

$8.35
+0.56 (+7.19%)
(As of 03/1/2024 ET)
Today's Range
$8.02
$8.52
50-Day Range
$5.37
$8.35
52-Week Range
$4.14
$9.37
Volume
4.13 million shs
Average Volume
1.52 million shs
Market Capitalization
$3.39 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.62

GoodRx MarketRank™ Stock Analysis

Analyst Rating
Hold
2.39 Rating Score
Upside/​Downside
3.2% Upside
$8.62 Price Target
Short Interest
Bearish
12.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.68mentions of GoodRx in the last 14 days
Based on 59 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
64.29%
From $0.14 to $0.23 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.96 out of 5 stars

Medical Sector

804th out of 950 stocks

Data Processing & Preparation Industry

46th out of 56 stocks


GDRX stock logo

About GoodRx Stock (NASDAQ:GDRX)

GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. GoodRx Holdings, Inc. was incorporated in 2015 and is headquartered in Santa Monica, California.

GDRX Stock Price History

GDRX Stock News Headlines

This healthcare stock making a buzz with 160% growth (GDRX)
Healthcare stocks are typically on the boring side of the spectrum, that is until you add a bit of technology and the right niche to them.
This healthcare stock making a buzz with 160% growth
Investing in healthcare stocks may not seem very exciting. This group of low-beta stocks serves as a defensive area of the consumer staples sector without much growth or activity.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Gene therapy: Why does it cost millions for a single treatment?
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. The shot heard around the world in the medical sector occurred on December 8, 2023, when the U.S. FDA approved Casgevy, the first FDA-approved gene-editing treatment for sickle cell disease (SCD) from Vertex Pharmaceuticals Inc. NASDAQ: VRTX and co-developed by CRISPR Therapeutics AG NASDAQ: CRSP.
Gene therapy: Why does it cost millions for a single treatment? (GDRX)
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Trade GoodRx? What's the Rush?
Why GoodRx Stock Soared Today
GoodRx Shares Rise On Improved Revenue, Outlook
See More Headlines
Receive GDRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GoodRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
3/02/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Data processing & preparation
Sub-Industry
N/A
Current Symbol
NASDAQ:GDRX
Fax
N/A
Employees
952
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.62
High Stock Price Target
$14.00
Low Stock Price Target
$4.50
Potential Upside/Downside
+3.2%
Consensus Rating
Hold
Rating Score (0-4)
2.39
Research Coverage
18 Analysts

Profitability

Net Income
$-32,830,000.00
Pretax Margin
-4.84%

Debt

Sales & Book Value

Annual Sales
$750.27 million
Cash Flow
$0.24 per share
Book Value
$2.05 per share

Miscellaneous

Free Float
400,568,000
Market Cap
$3.39 billion
Optionable
Optionable
Beta
1.43
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report














GDRX Stock Analysis - Frequently Asked Questions

Should I buy or sell GoodRx stock right now?

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GoodRx in the last year. There are currently 1 sell rating, 9 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GDRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GDRX, but not buy additional shares or sell existing shares.
View GDRX analyst ratings
or view top-rated stocks.

What is GoodRx's stock price target for 2024?

18 brokers have issued 12 month price objectives for GoodRx's shares. Their GDRX share price targets range from $4.50 to $14.00. On average, they expect the company's share price to reach $8.62 in the next year. This suggests a possible upside of 3.2% from the stock's current price.
View analysts price targets for GDRX
or view top-rated stocks among Wall Street analysts.

How have GDRX shares performed in 2024?

GoodRx's stock was trading at $6.70 at the beginning of 2024. Since then, GDRX stock has increased by 24.6% and is now trading at $8.35.
View the best growth stocks for 2024 here
.

When is GoodRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our GDRX earnings forecast
.

How were GoodRx's earnings last quarter?

GoodRx Holdings, Inc. (NASDAQ:GDRX) issued its quarterly earnings results on Thursday, November, 9th. The company reported $0.06 earnings per share for the quarter, meeting analysts' consensus estimates of $0.06. The business earned $180 million during the quarter, compared to analyst estimates of $188.52 million. GoodRx had a positive trailing twelve-month return on equity of 2.37% and a negative net margin of 1.18%. The company's quarterly revenue was down 3.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.07 EPS.

What ETFs hold GoodRx's stock?
What guidance has GoodRx issued on next quarter's earnings?

GoodRx updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $800.0 million-$800.0 million, compared to the consensus revenue estimate of $790.5 million.

What other stocks do shareholders of GoodRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GoodRx investors own include Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Bristol-Myers Squibb (BMY), DraftKings (DKNG), GW Pharmaceuticals (GWPH), Rocket Companies (RKT), AT&T (T), Advanced Micro Devices (AMD) and Alteryx (AYX).

When did GoodRx IPO?

(GDRX) raised $900 million in an initial public offering (IPO) on Wednesday, September 23rd 2020. The company issued 34,600,000 shares at $24.00-$28.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and Barclays acted as the underwriters for the IPO and BofA Securities, Citigroup, Credit Suisse, RBC Capital Markets, UBS Investment Bank, Cowen, Deutsche Bank Securities, Evercore ISI, Citizens Capital Markets, KKR, LionTree, Raymond James, SVB Leerink, Academy Securities, Loop Capital Markets, R. Seelaus and Ramirez were co-managers.

Who are GoodRx's major shareholders?

GoodRx's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.06%), Rubric Capital Management LP (1.45%), Dimensional Fund Advisors LP (0.44%), Rip Road Capital Partners LP (0.43%), Assenagon Asset Management S.A. (0.33%) and Invenomic Capital Management LP (0.12%). Insiders that own company stock include Abdiel Capital Management, Llc, Agnes Rey-Giraud, Andrew Slutsky, Babak Azad, Bansi Nagji, Douglas Joseph Hirsch, Idea Men, Llc, Karsten Voermann, Lake Group LLC Silver, Scott Wagner and Trevor Bezdek.
View institutional ownership trends
.

How do I buy shares of GoodRx?

Shares of GDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GDRX) was last updated on 3/3/2024 by MarketBeat.com Staff